Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05858138
Other study ID # REC110-74
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 3, 2022
Est. completion date December 31, 2023

Study information

Verified date May 2023
Source Taichung Tzu Chi Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to explore the effectiveness of Jing-Si Herbal Tea on improving the Non-alcoholic fatty liver disease patients


Description:

This study adopted a randomized double-blind design, 2-arm trial study. All eligible patients included in the study agreed to participated and signed the informed consent from and the study procedures were approved by the ethical committee of Taichung Tzu Chi general hospital (REC110-74). Patients were recruited from the Gastroenterology department of Taichung Tzu Chi hospital. After random assignment to 2 groups, patients will receive Jing-Si Herbal Tea or placebo twice a day for 24 weeks. We will evaluate the blood test results, abdominal ultrasound and physical examination every 12 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: - Sign the Informed consent - Age between 20-70 - Diagnosis for moderated NAFLD - Liver disease without hepatic decompensation - HbA1c < = 8.0 % Exclusion Criteria: - Do not sign the Informed consent - Other related liver diseases will affect the study which evaluated by physicians - Women of potential pregnancy or pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Jing-Si Herbal Tea
patient will receive twice in a day for 24 weeks
Placebo Jing-Si Herbal Tea
Placebo Jing-Si Herbal Tea

Locations

Country Name City State
Taiwan Taichung Tzu Chi Hospital Taichung

Sponsors (1)

Lead Sponsor Collaborator
Taichung Tzu Chi Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessing the changes from baseline blood glucose at 24 week Collect the data of blood glucose from blood test 24 week
Primary Assessing the changes from baseline GOT (Glutamic Oxaloacetic Transaminase) at 24 week Collect the data of GOT from blood test 24 week
Primary Assessing the changes from baseline GPT (Glutamic Pyruvic Transaminase) at 24 week Collect the data of GPT from blood test 24 week
Primary Assessing the changes from baseline total cholesterol at 24 week Collect the data of total cholesterol from blood test 24 week
Primary Assessing the changes from baseline triglycerides at 24 week Collect the data of triglycerides from blood test 24 week
Primary Assessing the changes from baseline HDL-C at 24 week Collect the data of HDL-C from blood test 24 week
Primary Assessing the changes from baseline LDL-C at 24 week Collect the data of LDL-C from blood test 24 weekk
Primary Assessing the changes from baseline NAFLD activity at 24 week Scoring the level of NAFLD activity 24 week
Primary Assessing the changes from baseline BMI at 24 week Collect the body height and body weight, weight and height will be combined to report BMI in kg/m^2 24 week
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4